Inception of Alkem Laboratories Limited

First manufacturing unit was established at Taloja near Mumbai

Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005

First research and development facility established at Taloja

Taxim became India’s first anti-infective drug to surpass sales figure of Rs. 1,000 million in the domestic market

Filed the first ANDA in the United States for the drug Amoldipine

Received the first ANDA in the United States for the drug Amoldipine

Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia

Acquired Ascend Laboratories, pharmaceutical company in the United States

Acquired Enzene, a company engaged in the development of biosimilars in India

Acquired an API manufacturing facility in the United States

Acquired the ‘Clindac-A’ brand in India from Galderma S.A.

Clavam surpassed Rs. 2,000 million domestic sales figure

Acquired a formulation manufacturing facility in the United States

Successfully completed Initial Public Offering (IPO)

Marketing alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India

Direct consumer marketing for Pregakem and Livoerb

Revenue from the US market crossed US$ 200 mn in annual sales

Crossed the revenue milestone of US$1 billion

Started new formulation manufacturing facility in Indore

Started a new biologic/biosimilar manufacturing facility in Pune

First product launched from Enzene Biosciences in India

Company forayed in the respiratory segment in India with the launch of Pulmocare division